SCHEMBL23294818

SCHEMBL23294818

CN(C)C1CCN(c2ccc(-c3ccc4nc5cccc(N6CCC(N(C)C)CC6)c5n4c3)cc2Br)CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CA P42336 2/20 0.37
▸ PDCD1 Q15116 1/20 0.37
▸ CD274 Q9NZQ7 1/20 0.37
▸ KCNH2 Q12809 4/20 0.35
▸ EIF4E P06730 1/20 0.35
▸ MKNK1 Q9BUB5 1/20 0.35
▸ MKNK2 Q9HBH9 1/20 0.35
▸ HTR6 P50406 4/20 0.34
▸ MAOB P27338 2/20 0.34
▸ MET P08581 1/20 0.34
▸ PDE3B Q13370 1/20 0.34
▸ PDE3A Q14432 1/20 0.34
▸ CYP2D6 P10635 3/20 0.32
▸ HRH1 P35367 3/20 0.32
▸ ACVR1 Q04771 1/20 0.32
▸ HTR1D P28221 2/20 0.32
▸ HTR3A P46098 2/20 0.32
▸ TMEM97 Q5BJF2 2/20 0.32
▸ MAPK8 P45983 2/20 0.32
▸ BTK Q06187 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23294875 0.89 MAOB (0.38) PIK3CAPDCD1CD274KCNH2EIF4E
SCHEMBL23294788 0.88 PIK3CD (0.37) PIK3CAPDCD1CD274KCNH2EIF4E
SCHEMBL23294917 0.87 PIK3CA (0.36) PIK3CAPDCD1CD274KCNH2EIF4E
SCHEMBL23294861 0.86 KCNH2 (0.37) PIK3CAPDCD1CD274KCNH2EIF4E
SCHEMBL23294790 0.85 CYP1A2 (0.37) PIK3CAPDCD1CD274KCNH2EIF4E
SCHEMBL23294810 0.83 ASIC3 (0.41) KCNH2PDE3BPDE3A
SCHEMBL23294791 0.82 MAOB (0.34) PIK3CAPDCD1CD274KCNH2EIF4E
SCHEMBL23294805 0.82 PIK3CA (0.39) PIK3CAPDCD1CD274KCNH2EIF4E
SCHEMBL23294866 0.81 CSF1R (0.34) PIK3CAPDCD1CD274KCNH2EIF4E
SCHEMBL23294825 0.81 PIK3CD (0.35) PIK3CAPDCD1CD274METPDE3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11547703-B2 Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof Impact Therapeutics (Shanghai), Inc (CN) 2023-01-10 — — US claimed
US-20210128535-A1 Substituted Fused Heteroaromatic Tricyclic Compounds as Kinase Inhibitors and The Use Thereof IMPACT THERAPEUTICS, INC. (CN) 2021-05-06 — — US claimed
US-11547703-B2 Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof Impact Therapeutics (Shanghai), Inc (CN) 2023-01-10 — — US disclosed
US-20210128535-A1 Substituted Fused Heteroaromatic Tricyclic Compounds as Kinase Inhibitors and The Use Thereof IMPACT THERAPEUTICS, INC. (CN) 2021-05-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210128535-A1 Substituted Fused Heteroaromatic Tricyclic Compounds as Kinase Inhibitors and The Use Thereof CHEK2, CHEK1, ATM PIK3CA 93/4885PDCD1 728/4885CD274 1598/4885
US-11547703-B2 Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof CHEK2, CHEK1, ATM PIK3CA 93/4885PDCD1 728/4885CD274 1598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback